Evidence map›Paper›PMID 42089033›Full record

ReviewContemporary oncology (Poznan, Poland)2026

When two lives intersect: melanoma in pregnancy: mechanisms, risks, and management strategies.

Svetoslava Troyanova Slavkova, Dimitar Slavkov

Abstract readReview
In one paragraph

Review in Contemporary oncology (Poznan, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Svetoslava Troyanova Slavkova *Helios Vogtland Klinikum Plauen, Plauen, Germany.
Dimitar Slavkov *Helios Vogtland Klinikum Plauen, Plauen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pregnancy-associated melanoma is one of the more frequently encountered malignancies during gestation, although its overall incidence remains low. Current evidence suggests that pregnancy itself does not adversely affect melanoma-specific survival when the tumour stage is considered, yet clinical management remains challenging. Physiological skin changes can obscure early detection, and limitations on imaging modalities and systemic therapies restrict standard diagnostic and treatment options. Additional uncertainty surrounds the safety and timing of sentinel lymph node biopsy during pregnancy. Although metastases to the placenta or foetus are exceedingly rare, placental histopathological examination is recommended in cases of advanced maternal disease to ensure appropriate follow-up. Optimal care relies on applying standard melanoma treatment principles with thoughtful adjustments to safeguard foetal well-being. Continued research and larger, higher-quality datasets are essential to improve prognostic accuracy and guide evidence-based management in this complex and clinically sensitive setting, supporting clinicians in delivering safer care for affected pregnant patients.

Indexed as

dermatologic oncologyfoetal involvementimaging in pregnancymaternal outcomesmelanoma managementmelanoma prognosisplacental metastasispregnancy-associated melanoma

Identifiers

PMID42089033
PMCPMC13137421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.